前列腺切除术后挽救放疗前PSA水平与长期抗雄激素治疗结局的关联
该研究为RTOG 9601随机临床试验的二次分析,纳入760例根治性前列腺切除术后生化复发患者,随机接受挽救放疗联合比卡鲁胺或安慰剂2年,按挽救放疗前PSA水平分层分析。结果显示PSA>1.5 ng/mL者联合抗雄激素治疗有总生存获益,而PSA≤0.6 ng/mL者无获益且其他原因死亡风险及心脏神经毒性风险增加。
要点
- 挽救放疗前PSA>1.5 ng/mL患者,联合比卡鲁胺有总生存获益(12年绝对获益25%)。
- PSA≤0.6 ng/mL患者联合治疗无生存获益,其他原因死亡及心脏神经毒性风险增加。
- PSA 0.61–1.5 ng/mL亚组分析显示联合治疗与总生存获益相关(HR 0.61)。
核心结论
- 挽救放疗前PSA水平可能是预测抗雄激素治疗联合挽救放疗获益的生物标志物。
- PSA>0.6 ng/mL者接受晚期挽救放疗时联合激素治疗与结局改善相关。
- PSA≤0.6 ng/mL者接受早期挽救放疗时长期抗雄激素治疗未改善总生存。
研究设计与样本
- RTOG 9601多中心双盲安慰剂对照随机临床试验的二次分析,1998至2003年开展。
- 纳入760例根治性前列腺切除术后切缘阳性或病理T3期、挽救放疗前PSA 0.2–4.0 ng/mL的患者。
- 随机分配至挽救放疗联合比卡鲁胺150 mg/d或安慰剂,疗程2年。
- 中位年龄65岁(范围40–83岁)。
主要发现
- PSA>1.5 ng/mL亚组(n=118)联合抗雄激素治疗与总生存获益相关,12年绝对获益25%(HR 0.45;95%CI 0.25–0.81)。
- PSA≤1.5 ng/mL亚组(n=642)联合治疗与总生存无显著关联(12年绝对差异1%;HR 0.87;95%CI 0.66–1.16)。
- PSA 0.61–1.5 ng/mL亚组(n=253)联合治疗与总生存获益相关(HR 0.61;95%CI 0.39–0.94)。
关键数值与推荐
- PSA分层采用方案预设的1.5 ng/mL界值及额外切点(包括0.6 ng/mL)。
- 主要终点为总生存,次要终点包括远处转移、其他原因死亡及3–5级心脏和神经毒性。
临床怎么用
- 对于根治性前列腺切除术后生化复发患者,挽救放疗前PSA水平可用于个体化决定是否联合长期抗雄激素治疗。
- PSA>0.6 ng/mL者可考虑联合比卡鲁胺治疗,PSA≤0.6 ng/mL者应权衡获益与毒性风险。
局限性
- 本研究为二次分析,结果需未来随机临床试验验证。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In men with recurrent prostate cancer, addition of long-term antiandrogen therapy to salvage radiotherapy (SRT) was associated with overall survival (OS) in the NRG/RTOG 9601 study. However, hormone therapy has associated morbidity, and there are no validated predictive biomarkers to identify which patients derive most benefit from treatment. OBJECTIVE: To examine the role of pre-SRT prostate-specific antigen (PSA) levels to personalize hormone therapy use with SRT. INTERVENTIONS: Men were randomized to SRT plus high-dose nonsteroidal antiandrogen (bicalutamide, 150 mg/d) or placebo for 2 years. DESIGN, SETTING, AND PARTICIPANTS: In this secondary analysis of the multicenter RTOG 9601 double-blind, placebo-controlled randomized clinical trial conducted from 1998 to 2003 by a multinational cooperative group, men with a positive surgical margin or pathologic T3 disease after radical prostatectomy with pre-SRT PSA of 0.2 to 4.0 ng/mL were included. Analysis was performed between March 4, 2019, and December 20, 2019. MAIN OUTCOMES AND MEASURES: The primary outcome was overall survival (OS). Secondary end points included distant metastasis (DM), other-cause mortality (OCM), and grades 3 to 5 cardiac and neurologic toxic effects. Subgroup analyses were performed using the protocol-specified PSA stratification variable (1.5 ng/mL) and additional PSA cut points, including test for interaction. Competing risk analyses were performed for DM and other-cause mortality (OCM). RESULTS: Overall, 760 men with PSA elevation after radical prostatectomy for prostate cancer were included. The median (range) age of particpants was 65 (40-83) years. Antiandrogen assignment was associated with an OS benefit in the PSA stratum greater than 1.5 ng/mL (n = 118) with a 25% 12-year absolute benefit (hazard ratio [HR], 0.45; 95% CI, 0.25-0.81), but not in the PSA of 1.5 ng/mL or less stratum (n = 642) (1% 12-year absolute difference; HR, 0.87; 95% CI, 0.66-1.16). In a subanalysis of men with PSA of 0.61 to 1.5 (n = 253), there was an OS benefit associated with antiandrogen assignment (HR, 0.61; 95% CI, 0.39-0.94). In those receiving early SRT (PSA ≤0.6 ng/mL, n = 389), there was no improvement in OS (HR, 1.16; 95% CI, 0.79-1.70), an increased OCM hazard (subdistribution HR, 1.94; 95% CI, 1.17-3.20; P = .01), and an increased odds of late grades 3 to 5 cardiac and neurologic toxic effects (odds ratio, 3.57; 95% CI, 1.09-15.97; P = .05). CONCLUSIONS AND RELEVANCE: These results suggest that pre-SRT PSA level may be a prognostic biomarker for outcomes of antiandrogen treatment with SRT. In patients receiving late SRT (PSA >0.6 ng/mL, hormone therapy was associated with improved outcomes. In men receiving early SRT (PSA ≤0.6 ng/mL), long-term antiandrogen treatment was not associated with improved OS. Future randomized clinical trials are needed to determine hormonal therapy benefit in this population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00002874.
引用
- Dess RT, Sun Y, Jackson WC, et al. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020. PMID: 32215583. doi:10.1001/jamaoncol.2020.0109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。